

ICP/AES /

/

(NJC)

(2005/6/22) (2004/ 6 / 16)

Coppered homogenate (MA-A1)

. ICP/AES

98.19% (1:1) (HClO₄:H₂O₂). 90.91% ° 450 (HCl:H₂O)(1:1)

()

, (60-15)

Abstract

Many concentrated acids or their mixtures were used to complete the digestion of the certified reference material type (MA-A1) which was used for the determination of chromium in it using Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP/AES).

It was found that the mixture (HClO₄:H₂O₂)(1:1) was to be the best for chromium determination with recovery of (98.19)% and (HCl:H₂O)(1:1) as a second proper acid for chromium analysis. This method was applied on twenty tissue samples of patients with breast tumors aged (15-60) years to determine chromium concentration.

Chromium concentrations in sera samples of the same patients were also measured and deficiency in chromium concentration values were appeared in sera of patients with breast cancer compared with benign cases.

, (Histidine)

(6-5)

.(0,+2,+3,+6)

(7)

(1)

(8)

(3,2)

(16)

RNA

/

(2)

DNA

(ICP/AES)

(10-

,⁽⁴⁾ (200-50)µg/day

9)

25%

(5)

.(ICP/AES)

Aparastus

:

(4)

-

.a

Poly vace E970,Higher

Analytical-England

RF-Generator; AMN-PS-1, plasma therm .b
 Vertical Direct Sample Introduction(VDSI) .c
 Fassel torch .d
 Cell .e
 Homogenizer MSK ,shaking action, 2000 and 4000rpm. .f
 Lypholizer(GT₂)Leyold-Heraeus(LH)
 Heraeus type .g
 MR.170E, Temperature range(100-1000C°)
 0.5

Chemicals :

Homogenizer : Aldrich .a
 Chromium nitrate [Cr(NO₃)₂] (1000µg/ml)
 Lypholizer
 25 : BDH .b
 Perchloric acid 60% .1
 Nitric acid 70.5% .2
 ICP/AES Hydrogen perxide 35% .3
 (0.05- : Fluka .c
 (r²=0.9986) 0.35)µg/ml Hydrochoric acid 37% .d
 Copped
 Homogenate (MA-A1)
 International Laboratory of
 Marine Radioactivity

Procedure :

0.5

(HCl:H₂O₂)(1:1)

(11)

, ° 450

(Rec%=90.91)

(1)

(12)

(HClO₄:H₂O₂) (1:1)

(Rec%=98.19)

:(1)

Type of acid or its mixture	Cr Conc. C.V=1.1 (ppm)			
	A.V (ppm) ± SD	E	E%	Rec%
Conc. HNO ₃	1.99±0.1	0.89	80.9	119.1
(5:1) (HNO ₃ :HClO ₄)	1.47±0.22	0.37	33.6	133.6
(4:1) (HNO ₃ :HClO ₄)	1.6±0.12	0.5	45.4	145.4
(3:1) (HNO ₃ :HClO ₄)	1.89±0.11	0.79	71.8	171.8
(2:1) (HNO ₃ :HClO ₄)	1.73±0.15	0.63	57.2	157.2
(1:1) (HNO ₃ :HClO ₄)	0.88±0.08	0.22	20.0	80.0
(1:1) (HNO ₃ :H ₂ O ₂)	1.34±0.15	0.24	21.8	121.8
(1:1) (HClO ₄ :H ₂ O ₂)	1.12±0.03	0.02	1.8	101.8
(4:1) (HNO ₃ :HCl)	1.57±0.11	0.47	47.2	142.7
(1:1) (HCl:H ₂ O) after ashing at 450°C	1.21±0.09	0.10	10	110.1
(4:1) (HNO ₃ :HClO ₄) after ashing at 450°C	1.99±0.17	0.80	80.9	180.9
(1:1) (HNO ₃ :H ₂ O ₂) after ashing at 450°C	2.03±0.12	0.93	84.5	184.5

C.V : Certified value

A.V : Analytical value

Rec%: Recovery %

(HClO₄:H₂O₂) (1:1)(HCl:H₂O₂)(1:1)

(2)

. ⁽¹²⁾ AAS

ICP/AES AAS

: (2)

Type of acid or its mixture	Cr Conc. C.V=1.1 (ppm)					
	A.V (ppm) ± SD by AAS	E	Rec%	A.V (ppm) ± SD by ICP/AES	E	Rec%
Conc. HNO ₃	2.30±0.36	1.20	209.08	1.99±0.1	0.89	119.1
(5:1) (HNO ₃ :HClO ₄)	1.40±0.36	0.30	127.27	1.47±0.22	0.37	133.6
(4:1) (HNO ₃ :HClO ₄)	1.25±0.23	0.15	113.63	1.6±0.12	0.5	145.4
(3:1) (HNO ₃ :HClO ₄)	1.62±0.16	0.52	147.27	1.89±0.11	0.79	171.8
(2:1) (HNO ₃ :HClO ₄)	1.50±0.06	0.40	136.36	1.73±0.15	0.63	157.2
(1:1) (HNO ₃ :HClO ₄)	0.71±0.10	0.61	155.75	0.88±0.08	0.22	80.0
(1:1) (HNO ₃ :H ₂ O ₂)	1.37±0.36	0.20	118.18	1.34±0.15	0.24	121.8
(1:1) (HClO ₄ :H ₂ O ₂)	1.05±0.05	0.05	98.45	1.12±0.03	0.02	101.8
(4:1) (HNO ₃ :HCl)	1.43±0.12	0.33	129.99	1.57±0.11	0.47	142.7
(1:1) (HCl:H ₂ O) after ashing at 450°C	1.00±0.1	-0.10	93.91	1.21±0.09	0.10	110.1
(4:1) (HNO ₃ :HClO ₄) after ashing at 450°C	2.50±0.28	1.40	227.26	1.99±0.17	0.80	180.9
(1:1) (HNO ₃ :H ₂ O ₂) after ashing at 450°C	1.92±0.11	0.82	174.54	2.03±0.12	0.93	184.5

(13)

, (3)

(HClO₄:H₂O₂) (1:1)

.(4)

ICP/AES

[]

/


(14)

(ICP/AES)

(15)


:(3)

Age group	Malignant		Benign		ANOVA
	N	Mean \pm SD	N	Mean \pm SD	C.S
<40	5	0.773 \pm 0.121	8	0.687 \pm 0.120	2.642 S
40<	4	0.613 \pm 0.091	3	1.10 \pm 0.213	



:(4)

Age group	Malignant		Benign		ANOVA
	N	Mean \pm SD	N	Mean \pm SD	C.S
<40	5	0.040 \pm 0.102	8	0.090 \pm 0.031	12.185 H.S
40<	4	0.023 \pm 0.011	3	0.065 \pm 0.009	



S: Significant

H.S: Highly significant

12. Samera H.H.; "A M.Sc. thesis submitted to the college of science, university of Baghdad"(2003).
13. Mulay I.L.; Roy R.; Knox B.; Suuhr N.; and Delaney W., *J.Nati. Cancer Inst.*, 1971, **47**, 1.
14. Mohamad A.AL-Hamadany, *National J. of Chem*, 2003, **12**, 610
15. Mohamad A.AL-Hamdany, R.K. AL-Kubaisy, Sameera H.H., *National J. of Chem.*, 2004, **13**, 1.
16. M.A. Farajzadeh , A.B. Monji, *Seperation and Purification Technology*, 2004, **38(3)**, 197.

References

1. Richard C.T.; Albert B.; David H.; and Robert R. "*Clinical Laboratory Medicine*"(London), 1992, **PP371**, 373.
2. Weatherall D.J.; "Oxford Textbook of Medicine" (New York)(1996) 3rd. Ed.,P1416-1426 .
3. Anderson R.A.; Polansky M.; and Bryden N., *Am. J. Nutr.*, 1991, **54**, 909.
4. John S.W.; and Christy M., "Minerals for Good Health" American Council on Pharmaceutical Education (ACPE) (2000),P83-91.
5. Timothy J.M.; "Chromium Containing Education Module"(ACPE) Oct.(1999).[Internet].
6. Mertz R.E.; and Reba R., *Am. J. Physiol.*, 1965, **209**, 489.
7. Carl A.B.; and Edward R., "Teitz Textbook of Clinical Chemistry "(London)(1999)3rd. Ed. Vol.2 ,P1046-1050.
8. Sherif L.R.; and Howard H., *Cancer Research* , 1984, **44**, 5390.
9. Nobrega J. J. , *Am. At. Spectrum*, 1998, **12**, 1239.
10. Liu C.; Guo-Yiharg Z.; and Xiaoliang T., *Journal Ca. Section*, 1997, **16**, 78 .
11. National Institute for Occupational Safety and Health (NIOSH), Manual of analytical methods,(1994),4th. Ed.PP:316.